references

  1. Moise KJ. Umbilical cord stem cells. Obstetrics & Gynecology. 2005;106(6):1393–1407.
  2. Stem cell basics I. National Institutes of Health website. http://stemcells.nih.gov/info/basics/1.htm. Accessed November 1, 2016.
  3. Data on File. Bloodworks Transplant list.
  4. Munoz J, Shah N, Rezvani K, et al. Concise review: Umbilical cord blood transplantation: Past, present, and future. Stem Cells Translational Medicine. 2014;3(12):1435–1443. doi:10.5966/sctm.2014-0151.
  5. Mahla RS. Stem cells applications in Regenerative medicine and disease Therapeutics. International Journal of Cell Biology. 2016;2016:1–24. doi:10.1155/2016/6940283.
  6. McGuckin CP, Forraz N. Potential for access to embryonic-like cells from human umbilical cord blood. Cell Proliferation. 2007;41:31–40. doi:10.1111/j.1365-2184.2008.00490.x.
  7. Roura S, Pujal J-M, Gálvez-Montón C, Bayes-Genis A. The role and potential of umbilical cord blood in an era of new therapies: A review. Stem Cell Research & Therapy. 2015;6(1). doi:10.1186/s13287-015-0113-2.
  8. Chaudhury S. Mesenchymal stem cell applications to tendon healing. Muscles, Ligaments and Tendons Journal. 2012;2(3):222-229.
  9. Krampera M, Pizzolo G, Aprili G, Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone. 2006;39(4):678–683. doi:10.1016/j.bone.2006.04.020.
  10. Tsai P-C, Fu T-W, Chen Y-MA, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat liver fibrosis. Liver Transplantation. 2009;15(5):484–495. doi:10.1002/lt.21715.
  11. Maurya DK, Doi C, Kawabata A, et al. Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer. 2010;10(1). doi:10.1186/1471-2407-10-590.
  12. Fu Y-S, Cheng Y-C, Lin M-YA, et al. Conversion of human Umbilical cord Mesenchymal stem cells in Wharton’s jelly to Dopaminergic Neurons in vitro: Potential therapeutic application for Parkinsonism. Stem Cells. 2006;24(1):115–124. doi:10.1634/stemcells.2005-0053.
  13. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12(6):R210. doi:10.1186/ar3187.
  14. Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS. A comparison of human bone Marrow–Derived Mesenchymal stem cells and human Umbilical Cord–Derived Mesenchymal Stromal cells for cartilage tissue engineering. Tissue Engineering Part A. 2009;15(8):2259–2266. doi:10.1089/ten.tea.2008.0393.
  15. Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s jelly Mesenchymal stem cells as candidates for beta cells regeneration: Extending the Differentiative and Immunomodulatory benefits of adult Mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Reviews and Reports. 2010;7(2):342–363. doi:10.1007/s12015-010-9196-4.
  16. Ding D-C, Shyu W-C, Chiang M-F, et al. Enhancement of neuroplasticity through upregulation of β1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiology of Disease. 2007;27(3):339–353. doi:10.1016/j.nbd.2007.06.010.
  17. Butler MG, Menitove JE. Umbilical cord blood banking: an update. Journal of Assisted Reproduction and Genetics. 2011;28(8):669-676. doi:10.1007/s10815-011-9577-x.
  18. Ichim TE, Solano F, Glenn E, et al. Stem cell therapy for autism. Journal of Translational Medicine. 2007;5(1):30. doi:10.1186/1479-5876-5-30.
  19. Ehrhart J, Darlington D, Kuzmin-Nichols N, et al. Biodistribution of infused human Umbilical cord blood cells in Alzheimer’s disease-like Murine model. Cell Transplantation. 2016;25(1):195–199. doi:10.3727/096368915x689604.
  20. Zhao Y, Jiang Z, Zhao T, et al. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Medicine. 2012;10(1). doi:10.1186/1741-7015-10-3.
  21. Zhao Y, Jiang Z, Zhao T, et al. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: Phase I/II clinical trial. BMC Medicine. 2013;11(1). doi:10.1186/1741-7015-11-160.
  22. China Spinal Cord Injury Network. Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT01471613. NLM Identifier: NCT01471613. Accessed November 1, 2016
  23. Li Q. Safety and Efficacy Investigation of Patients With Liver Cirrhosis by Transplantation of Umbilical Cord Blood Mononuclear Cells. Available from: https://clinicaltrials.gov/ct2/show/NCT01942915. NLM Identifier: NCT01942915. Accessed November 1, 2016
  24. Min K, Song J, Kang JY, et al. Umbilical cord blood therapy Potentiated with erythropoietin for children with cerebral palsy: A double-blind, Randomized, placebo-controlled trial. STEM CELLS. 2013;31(3):581–591. doi:10.1002/stem.1304.
  25. Ivy Institute of Stem Cells Co. Ltd. Safety and Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stem Cell Transplantation in Acute Lung Injury. Available from: https://clinicaltrials.gov/ct2/show/NCT02444455. NLM Identifier: NCT02444455. Accessed November 1, 2016.
  26. Dai J. Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells. Available from: https://clinicaltrials.gov/ct2/show/NCT02277145. NLM Identifier: NCT02277145. Accessed November 1, 2016.
  27. Lin S. Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke. Available from: https://clinicaltrials.gov/ct2/show/NCT02433509. NLM Identifier: NCT02433509. Accessed November 1, 2016.
  28. Huang P. Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Diabetes Secondary Peripheral Arterial Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02287831. NLM Identifier: NCT02287831. Accessed November 1, 2016.
  29. Cantero Peral S. Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01856049. NLM Identifier: NCT01856049. Accessed November 1, 2016
  30. Medipost Co Ltd. Randomized, Open-Label, Multi-Center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or Defect. Available from: https://clinicaltrials.gov/show/NCT01041001. NLM Identifier: NCT01041001. Accessed November 1, 2016.
  31. National Taiwan University Hospital. Phase 1 Study of Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Autoserum and Cord Blood Serum—in Vitro Cell Culture Experiment. Available from: https://clinicaltrials.gov/ct2/show/NCT00681642. NLM Identifier: NCT00681642. Accessed November 1, 2016.
  32. Kurtzberg J. Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD). Available from: https://clinicaltrials.gov/ct2/show/NCT02176317. NLM Identifier: NCT02176317. Accessed November 1, 2016.
  33. Kim A, Kim M, Kim S, et al. Stem-cell therapy for peripheral arterial occlusive disease. European Journal of Vascular and Endovascular Surgery. 2011;42(5):667–675. doi:10.1016/j.ejvs.2011.06.026.
  34. Lund RD, Wang S, Lu B, et al. Cells isolated from Umbilical cord tissue rescue Photoreceptors and visual functions in a rodent model of retinal disease. STEM CELLS. 2009;25(3):602–611. doi:10.1634/stemcells.2006-0308.
  35. Kim D-W, Staples M, Shinozuka K, Pantcheva P, Kang S-D, Borlongan C. Wharton’s jelly-derived Mesenchymal stem cells: Phenotypic characterization and optimizing their therapeutic potential for clinical applications. International Journal of Molecular Sciences. 2013;14(6):11692–11712. doi:10.3390/ijms140611692.
  36. Bongso A, Fong C-Y. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human Umbilical cord. Stem Cell Reviews and Reports. 2012;9(2):226–240. doi:10.1007/s12015-012-9418-z.
  37. Fan C-G, Zhang Q, Zhou J. Therapeutic potentials of Mesenchymal stem cells derived from human Umbilical cord. Stem Cell Reviews and Reports. 2010;7(1):195–207. doi:10.1007/s12015-010-9168-8.
  38. Shi S, Jia S, Liu J, Chen G. Accelerated regeneration of skin injury by Co-transplantation of Mesenchymal stem cells from Wharton’s jelly of the human Umbilical cord mixed with Microparticles. Cell Biochemistry and Biophysics. 2014;71(2):951–956. doi:10.1007/s12013-014-0292-y.
  39. Mayo Clinic Staff. Cirrohosis. Mayo Clinic website. http://www.mayoclinic.org/diseases-conditions/cirrhosis/home/ovc-20187218. Updated April 6, 2016. Accessed November 9, 2016.
  40. Mayo Clinic Staff. Pulmonary fibrosis. Mayo Clinic website. http://www.mayoclinic.org/diseases-conditions/pulmonary-fibrosis/home/ovc-20211752. Updated September 23, 2016. Accessed November 9, 2016.
  41. Hoffman JL, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900.
  42. A Can et al, Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia, (HUC-HEART Trial). Stem Cell Rev. 2015 Oct;11(5):752-60.
  43. Cell Adhesion and Migration: Kun Ling. Mayo Clinic website. http://www.mayo.edu/research/labs/cell-adhesion-migration/wound-healing?_ga=1.69056337.1918419582.1478728372. Accessed November 9, 2016.
  44. Mayo Clinic Staff. Spinal cord injury. Mayo Clinic website. http://www.mayoclinic.org/diseases-conditions/spinal-cord-injury/basics/definition/con-20023837?_ga=1.110566341.1918419582.1478728372. Updated October 8, 2014. Accessed November 9, 2016.
  45. Mayo Clinic Staff. Peripheral artery disease (PAD). Mayo Clinic website. http://www.mayoclinic.org/diseases-conditions/peripheral-artery-disease/home/ovc-20167418. Updated December 24, 2015. Accessed November 9, 2016.
  46. Hematopoietic Stem Cells. National Institutes of Health website. https://stemcells.nih.gov/info/2001report/chapter5.htm. Accessed November 9, 2016.
  47. Data accessed from Cord Blood Registry website on November 1, 2016.
  48. Data accessed from ViaCord website on November 1, 2016.
  49. Cord Blood Banking – Information for Consumers. U.S. Food and Drug Administration website. http://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/Consumers/ucm236044.htm. Updated July 23, 2012. Accessed November 10, 2016.
  50. Data on file. Bloodworks biologics license for HPC (hematopoietic progenitor cells), Cord Blood.
  51. Data on file. AABB accreditation to be provided by Natera.
  52. Data on file. CLIA certification to be provided by Natera
  53. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of Hematopoietic stem cell transplantation in the U.S. Biology of Blood and Marrow Transplantation. 2008;14(3):316–322. doi:10.1016/j.bbmt.2007.12.493.
  54. World Health Organization. Guideline: Delayed umbilical cord clamping for improved maternal and infant health and nutrition outcomes. Geneva: World Health Organization, 2014.
  55. Andersson O, Hellström-Westas L, Andersson D, Clausen J, Domellöf M. Effects of delayed compared with early umbilical cord clamping on maternal postpartum hemorrhage and cord blood gas sampling: A randomized trial. Acta Obstetricia et Gynecologica Scandinavica. 2012;92(5):567–574. doi:10.1111/j.1600-0412.2012.01530.x.
  56. Downey CL, Bewley S. Historical perspectives on umbilical cord clamping and neonatal transition. Journal of the Royal Society of Medicine. 2012;105(8):325-329. doi:10.1258/jrsm.2012.110316.
  57. Garofalo M, Abenhaim HA. Early versus delayed cord clamping in term and Preterm births: A review. Journal of Obstetrics and Gynaecology Canada. 2012;34(6):525–531. doi:10.1016/s1701-2163(16)35268-9.
  58. Hutchon DJR. Immediate or early cord clamping vs delayed clamping. Journal of Obstetrics & Gynaecology. 2012;32(8):724–729. doi:10.3109/01443615.2012.721030.
  59. Kugelman A, Borenstein-Levin L, Riskin A, et al. Immediate versus delayed Umbilical cord clamping in premature Neonates born < 35 weeks: A prospective, Randomized, controlled study. American Journal of Perinatology. 2007;24(5):307–315. doi:10.1055/s-2007-981434.
  60. Oh W, Fanaroff AA, Carlo WA, Donovan EF, McDonald SA, Poole WK. Effects of delayed cord clamping in very-low-birth-weight infants. Journal of Perinatology. 2011;31:S68–S71. doi:10.1038/jp.2010.186.
  61. Sommers R, Stonestreet BS, Oh W, et al. Hemodynamic effects of delayed cord clamping in premature infants. PEDIATRICS. 2012;129(3):e667–e672. doi:10.1542/peds.2011-2550.
  62. Ononeze ABO, Hutchon DJR. Attitude of obstetricians towards delayed cord clamping: A questionnaire-based study. Journal of Obstetrics & Gynaecology. 2009;29(3):223–224. doi:10.1080/01443610802712918.
  63. Sivaraman T, Arulkumaran S. Delayed umbilical cord clamping: Potential for change in obstetric practice. BJOG: An International Journal of Obstetrics & Gynaecology. 2011;118(6):767–767. doi:10.1111/j.1471-0528.2011.02897.x.
  64. Revelant J. Why some moms are asking doctors to delay cutting their baby’s umbilical cord. Fox News. May 24, 2015. http://www.foxnews.com/health/2015/05/24/why-some-moms-are-asking-doctors-to-delay-cutting-their-babys-umbilical-cord.html. Accessed November 14, 2016.
  65. Probability calculation based on Mendelian inheritance of HLA haplotypes.
  66. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Human and Health Services. Guidance for the Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoetic Reconstitution for Specified Indications. 2009.
  67. Broxmeyer HE, Lee M, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773–4777. doi:10.1182/blood-2011-01-330514.
  68. Mayo Clinic Staff. Breakthrough Stem Cell Treatment for HLHS Patients. Mayo Clinic Website. http://hlhsblog.mayoclinic.org/discussion/breakthrough-stem-cell-treatment-for-hlhs-patients/. Last accessed January 4, 2017.
  69. Abdullah Y. Cord blood banking: what nurses and healthcare providers should know. MCN Am J Matern Child Nurs. 2011;36(6):344-50.
  70. The American Academy of Anti-Aging Medicine. What is stem cell therapy? http://www.a4m.com/fellowship-stem-cell-overview-what-is-stem-cell-therapy.html. Last accessed January 5, 2017.
  71. Trounson A, McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell Review. 2015; 17: 11-22.
  72. Nietfield JJ, Pasquini MC, Logan BR, Verter, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14:316-322.
  73. United States Government Accountability Office. National Cord Blood Inventory. Practices for Increasing Availability for Transplants and Related Challenges. 2011.
  74. Parents.com. Jeanette Moninger. Pregnancy & Birth. My Developing Baby. Cord Blood Banking. The Cord Blood Controversy. http://www.parents.com/pregnancy/my-baby/cord-blood-banking/the-cord-blood-controversy/. Accessed January 6, 2017.
  75. Parent’s Guide to Cord Blood Foundation. US Regulations. https://parentsguidecordblood.org/en/regulations. Accessed January 6, 2017.
  76. Gluckman et al. Outcome of cord blood transplantation from related and unrelated donors. N Engl J Med. 1997;337:373-81.
  77. Data on File. TechValidate Study. Performed December 2016.
  78. Orchard PJ et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015;126(2):270-276.
  79. Schmidt D et al. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg. 2004 Dec;78(6):2094-8.
  80. Baumgartner J. Safety of Autologous Stem Cell Infusion for Children with Acquired Hearing Loss. Available from: https://clinicaltrials.gov/ct2/show/NCT02038972. ClinicalTrials.gov Identifier: NCT02038972. Accessed January 19, 2017.
  81. Wyles CC, Houdek MT, Behfar A, Sierra RJ. Mesenchymal stem cell therapy for osteoarthritis: current perspectives. Stem Cells and Cloning: Advances and Applications 2015:8 117–124.
  82. FDA NDA approved and CE marked under the Medical Devices Directive for the collection of cord blood. https://www.pall.com/pdfs/Medical/092682_CordBlood_Exterior_SS.pdf. Last accessed January 19, 2017.
  83. Centers for Disease Control. National Diabetes Statistics Report 2014. https://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html. Last accessed January 24, 2017.
  84. American Liver Foundation. Liver disease: the big picture. http://www.liverfoundation.org/education/liverlowdown/ll1013/bigpicture/. Last accessed January 24, 2017.
  85. Johnson ER, Matthay MA. Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010;23(4): 243-252.
  86. CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed January 24, 2017.
  87. National Institute of Health. U.S. Department of Health and Human Services. Facts about peripheral arterial disease. https://www.nhlbi.nih.gov/health/educational/pad/docs/pad_extfctsht_general_508.pdf. Last accessed January 24, 2017.
  88. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—2015 update: A report from the American Heart Association. Circulation. 2015; 131(4):e29-322.
  89. Prevent Blindness. The Scope of Eye Injury Problem. http://www.preventblindness.org/sites/default/files/national/documents/fact_sheets/FS93_ScopeEyeInjury_0.pdf. Last accessed January 24, 2017.
  90. National Spinal Cord Injury Statistical Center, Birmingham, Alabama. Spina lCord Injury Facts and Figures at a Glance. https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202012%20Feb%20Final.pdf. Last accessed January 24, 2017.
  91. Centers for Disease Control and Prevention. Data and statistics for Cerebral Palsy. https://www.cdc.gov/ncbddd/cp/data.html. Last accessed January 24, 2017.
  92. Parkinson’s Disease Foundation. Statistics on Parkinson’s. http://www.pdf.org/en/parkinson_statistics. Last accessed January 24, 2017.
  93. UCSF Medical Center. Cartilage repair. https://www.ucsfhealth.org/treatments/cartilage_repair/. Last accessed January 24, 2017.
  94. Clinical Trials.gov. Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis. https://www.clinicaltrials.gov/ct2/show/NCT02643823?term=%22rheumatoid+arthritis%22+AND+%22umbilical%22&rank=1 Last accessed January 25, 2017.
  95. Wang L et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013;22(24):3192-202.
  96. Arthritis Foundation. What is rheumatoid arthritis. http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php. Last accessed January 25, 2017.
  97. National Institute of Health. NIH Fact Sheets. Osteoarthritis. https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=55. Last accessed January 25, 2017.
  98. Rush University Medical Center. Stem cell therapy to repair damaged knee cartilage. Press Release. January 24, 2013. https://www.rush.edu/news/press-releases/rush-researchers-studying-stem-cell-therapy-repair-damaged-knee-cartilage. Last accessed January 25, 2017.

Thank You for Visiting Evercord.com

To view the site please update your browser

The Evercord site works on all modern browsers with legacy support back through Internet Explorer 9. Please update by going to the link below.

Update Browser